V1RI5 inhibitors pertain to a class of chemical compounds designed to selectively bind to and inhibit the activity of the V1RI5 receptor, a protein associated with a specific biochemical pathway within cells. The nomenclature V1RI5 typically represents a placeholder for a specific receptor name, which may be related to a wide range of physiological processes. These inhibitors are crafted through a detailed understanding of molecular biology, biochemistry, and structural biology to ensure that they achieve high specificity and efficacy in their action. By binding to the V1RI5 receptor, these inhibitors can modulate the receptor's natural function, which is often a key factor in the regulation of complex biological mechanisms. The development of V1RI5 inhibitors involves the identification of critical interaction points within the receptor structure that are essential for its activity. Researchers employ various techniques, such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and computational modeling, to elucidate the three-dimensional structure of the receptors and to understand how inhibitors can effectively bind to these targets.
The chemical composition of V1RI5 inhibitors is diverse, encompassing a range of small molecules, peptides, or even antibody-based compounds. The structural complexity of these inhibitors can vary significantly, from relatively simple organic molecules to large and intricate biologics. The design process for these inhibitors involves iterative cycles of synthesis and testing to refine their ability to interact with the V1RI5 receptor with high affinity and selectivity. Advanced techniques such as high-throughput screening, combinatorial chemistry, and structure-based drug design play crucial roles in identifying potential inhibitors and optimizing their properties. These inhibitors are characterized by their unique chemical signatures, which include specific functional groups or moieties that are crucial for their activity. The physicochemical properties of these compounds, such as solubility, stability, and permeability, are also finely tuned to enhance their interaction with the V1RI5 receptor. The ultimate goal in the design of V1RI5 inhibitors is to achieve a compound that can precisely modulate the receptor's activity, which is a result of sophisticated chemical engineering and a deep understanding of the receptor's role in cellular physiology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $451.00 | 3 | |
This toxin ADP-ribosylates G proteins, thereby uncoupling G protein-coupled receptors (GPCRs) like V1RI5 from their associated G proteins, inhibiting downstream signaling. | ||||||
NF 449 | 389142-38-5 | sc-203159 | 10 mg | $314.00 | 5 | |
NF449 is a potent and selective inhibitor of Gαs protein. By inhibiting Gαs, it would prevent V1RI5, if coupled to Gαs, from transmitting signals inside the cell, thereby reducing its functional activity. | ||||||
YM 254890 | 568580-02-9 | sc-507356 | 1 mg | $510.00 | ||
A specific inhibitor of the Gαq/11 family of G proteins. If V1RI5 signals through Gαq/11, YM-254890 would block its associated signaling pathways. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
A potent inhibitor of Protein Kinase C (PKC). If V1RI5 leads to the activation of PKC through its signaling pathway, Go 6983 would inhibit this pathway, thus dampening V1RI5's signaling. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
Cdc42 inhibitor, which could impact actin cytoskeleton dynamics. Since GPCRs like V1RI5 may rely on proper cytoskeletal positioning for signaling, ML-141 could indirectly inhibit V1RI5 function by disrupting this interaction. | ||||||
Clozapine | 5786-21-0 | sc-200402 sc-200402A sc-200402B sc-200402C | 50 mg 500 mg 5 g 10 g | $69.00 $364.00 $2500.00 $4100.00 | 11 | |
An antagonist of several GPCRs and can act as a functional inhibitor of V1RI5 if it demonstrates antagonist activity at this receptor, thereby blocking its signaling capabilities. | ||||||
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $152.00 $214.00 $728.00 $2601.00 $10965.00 $21838.00 $41096.00 | 5 | |
It is a polysulfonated naphthylurea that inhibits various G protein-coupled receptors and growth factor signaling, which could lead to the inhibition of V1RI5 if it is involved in similar signaling pathways. | ||||||